This inventor holds 4 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2002-2012.
Location History:
- Weil, DE (2002)
- Weil am Rhein, DE (2011 - 2012)
Company Filing History:
Years Active: 2002-2012
Title: The Innovative Contributions of Sabine Pfeffer
Introduction
Sabine Pfeffer is a notable inventor based in Weil am Rhein, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the development of drug compounds and their formulations. With a total of 4 patents to her name, her work has had a considerable impact on the industry.
Latest Patents
Among her latest patents is a process for the preparation of rapamycin derivatives. This involves the production of a 32-deoxorapamycin from a 32-iodo- or 32-hydroxyrapamycin, where the hydroxy group is substituted by the residue of an arylthionocarbonate or an arylthiocarbamate, using tris(trimethylsilyl)-silan and α,α'-azo-isobutyronitril in an organic solvent. Another significant patent focuses on modifying drug crystal formation. This process provides a method for altering the crystal habit of acicular drug substances, along with the resulting crystals and specific modifications of mycophenolic acid or mycophenolate sodium.
Career Highlights
Sabine Pfeffer has worked with prominent companies in the pharmaceutical sector, including Novartis AG and Novartis Pharma GmbH. Her experience in these organizations has allowed her to refine her skills and contribute to groundbreaking research and development in drug formulation.
Collaborations
Throughout her career, Sabine has collaborated with esteemed colleagues such as Dierk Wieckhusen and Cornelia Dosenbach. These partnerships have fostered innovation and have been instrumental in advancing her research.
Conclusion
Sabine Pfeffer's contributions to the field of pharmaceuticals through her patents and collaborations highlight her role as a significant inventor. Her work continues to influence the development of new drug formulations and processes.